Reading the tape
NASDAQ: MDGL
Madrigal Pharmaceuticals, Inc.
Healthcare · Biotechnology
Market Cap
$11.66B
52w High
$615.00
52w Low
$265.00
P/E
-39.57
Volume
66.28K
Outstanding Shares
22.94M
Price vs Fundamentals
Why The Stock Is Moving
Fundamentals are supporting the moveModerate confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 69.29%Revenue (TTM): 432.05%FCF (TTM): 58.87%
What changed
The stock rose 69.29% over the last year. Revenue grew 432.05% over the trailing twelve months. Operating margin moved from -276.39% to -31.31%. Free cash flow grew 58.87% over the trailing twelve months.
What the market seems to be pricing
The stock move broadly lines up with stronger business momentum. The operating data is doing enough work that the move does not need an overvaluation story to explain it.
What would invalidate this read
Operating margin is at -31.31%. Revenue grew 432.05% — this thesis depends on that trajectory holding. If revenue growth, margins, or free cash flow roll over while the stock keeps climbing, more of the move would be coming from multiple expansion than business progress.
Company profile
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases.
CEOWilliam J. Sibold
SectorHealthcare
IndustryBiotechnology
Employees528
IPO dateFeb 6, 2007
Valuation
Forward P/E—
EV/EBITDA-49.99
Enterprise value$13.22B
Stock splits
Jul 25, 2016↓ Reverse
Every 35 shares became 1
Profitability & growth
Revenue growth210.77%
Gross margin94.14%▼2.48%vs FY2024
Operating margin-31.31%▲88.67%vs FY2024
ROE-47.83%▲22.55%vs FY2024
Analyst consensus
RatingBuy
Target price$728.00▲43.17%
20
Buy
2
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 6, 2026
Q2 FY26 · EPS est -$4.23 · Revenue est $301.07M
View